NCT02766777 - Evaluation of the Safety of Lubiprostone in Pediatric Participants Aged ≥ 6 Years to < 18 Years With Functional Constipation | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 12, 2016

Primary Completion Date

November 4, 2016

Study Completion Date

November 4, 2016

Conditions

Constipation - Functional

Interventions

DRUG

Lubiprostone

12 or 24 mcg soft capsules for oral administration.

Trial Locations (13)

22902

Pediatric Research of Charlottesville, LLC, Charlottesville

29303

Spartanburg Medical Research, Spartanburg

29414

Coastal Clinical Research, Charleston

29464

Coastal Pediatrics Associates - Mount Pleasant, Mt. Pleasant

45431

PriMed Clinical Research, Beavercreek

61602

Methodist Medical Center, Peoria

68005

Pioneer Clinical Research, Bellevue

71101

Willis-Knighton Physician Network, Shreveport

72703

Northwest Arkansas Pediatric Clinic, Fayetteville

78413

3rd Coast Research Associates, Corpus Christi

84075

Wee Care Pediatrics, Syracuse

84341

Bridgerland Clinical Research, Logan

97030

Cyn3rgy Research, Gresham

All Listed Sponsors

collaborator

Sucampo AG

INDUSTRY

lead

Sucampo Pharma Americas, LLC

INDUSTRY